Skip to main content
. 2014 Sep 25;6(1):471–483. doi: 10.18632/oncotarget.2509

Figure 3.

Figure 3

MiR-578, miR-573 and miR-122 in BRCA1/2 mutation carriers and BRCAX associated tumors: (A) Mean levels with S.E.M. (B) Percentage of the overexpression.